Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2026-05-05 Quarterly Report
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Quarterly Report 2026
Quarterly Report
2026-05-05 English
Quarterly Report 2026
Quarterly Report
2026-05-05 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing an increase in the number of shares and voting rights in Alligator Bioscience AB due to the exercise of warrants (TO 14), which constitutes a change in the company’s share capital and number of shares outstanding. This fits the definition of a Share Issue/Capital Change (Code: SHA).
2026-03-31 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Share Issue/Capital Change Classification · 1% confidence The document is a press release by Alligator Bioscience announcing the exercise of warrants and consequent increase in the number of outstanding shares and votes as of 31 March 2026. This constitutes changes in the company’s capital structure (new shares issued via warrant exercise). It is not an earnings release, management change, AGM material, or annual/interim report. It fits the criteria for Share Issue/Capital Change (Code: SHA).
2026-03-31 English
Kallelse till årsstämma i Alligator Bioscience AB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice (‘kallelse till årsstämma’) calling shareholders to the Annual General Meeting, outlining agenda items, proposals, voting procedures, proxy rules, and related information to solicit votes. This matches the definition of a Proxy Solicitation & Information Statement.
2026-03-30 Swedish
Notice of annual general meeting in Alligator Bioscience AB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the Annual General Meeting, detailing the time, place, agenda items, proposed resolutions, voting rights, proxy instructions, and board election information. It is sent to shareholders to provide information and solicit votes for the meeting, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.